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Abstract 
OBJECTIVE: This study aimed to investigate T & B lymphocyte subsets and Natural Killer (NK) cells patterns in 
children with FMF versus normal control subjects, to estimate the immunoglobulins IgG, IgM, and IgA levels, and 
to scrutinize the possible use of Neutrophil / Lymphocyte ratio (NLR) as a marker for subclinical inflammation in 
FMF patients. 
PATIENTS AND METHODS: A group of 42 patients with FMF attending the Genetics Clinic at National Research 
Centre were included in this study. They were 13 males and 19 females; their age ranged from 2 to 17 years old. 
Normal healthy subjects within the same age and sex range were included as a control group. Complete blood 
picture was done for all cases, and neutrophil/ lymphocyte ratio was calculated. Flow cytometer analysis was 
done for CD3, CD4, CD8, CD19 and CD16 using monoclonal antibodies. Immunoglobulins IgG, IgA and IgM were 
estimated in serum using nephelometry. 
RESULTS: Positive consanguinity was present in 20 patients (47.6%). Abdominal pain was the most common 
manifestation followed by fever, arthritis, and red rash. CD3, CD4 and CD8 were statistically increased in patients 
group as compared to normal control group, while CD16 was statistically decreased. 
CONCLUSION: The study suggests that quantitative measurement of CD expressions of CD3, CD4 and CD8 as 
well as NLR might be used as valuable markers for subclinical inflammation in FMF. 
 
 
 
 
 
Introduction 
 
Familial Mediterranean fever (FMF) is the 
most common systemic autoinflammatory disorder 
worldwide [1]. It is an autosomal recessive disease [2] 
that affects mainly the Mediterranean population [3], is 
characterised by recurrent self - limited fever and 
aseptic serosal inflammation, causing abdominal, 
thoracic and joints pain [4]. Children with FMF are 
more prone to growth retardation [5], chronic 
normocytic normochromic anaemia [6], and 
splenomegaly [7]. 
Malicious activation of many inflammatory 
pathways occurs during the attacks of FMF, in which 
T, B and Natural killer cells play a major role [8][9]. 
The interaction of these cells with endothelial cells 
and several inflammatory and immune mediators 
produced by these cells leads to the formation of 
atherosclerotic plaques followed by its destabilisation 
and vessel rupture [10]. 
In between attacks, inflammation continues 
subclinically with the associated processes of 
endothelial dysfunction, increased atherosclerotic 
changes and platelets activation. The persistent 
inflammation in FMF may cause endothelial 
dysfunction, atherothrombosis and systemic 
amyloidosis [11]. The Neutrophil / Lymphocyte ratio 
(N/L ratio) showed significant, rapid, and serial 
changes as immune system response to different 
conditions like surgical stress, systemic inflammation 
or severe infections [12], and can be used as a 
marker for predicting amyloidosis development [13]. 
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The most distressing complication in FMF is 
renal amyloidosis, leading to nephrotic syndrome and 
chronic kidney failure. A macromolecular complex, 
called inflammasome, plays a major role in the 
activation of IL - 1 and thus induction of inflammation 
and when inflammasome activity is abnormally 
stimulated through a mutation, it may be involved in 
the pathogenesis of FMF [14][15][16]. Natural killer 
(NK) cells are cytotoxic lymphocytes that participate in 
innate immunity. In addition to their cytotoxic 
response, these cells produce cytokines to assist the 
adaptive immune response [17][18]. 
The aim of this study was to investigate T and 
B lymphocytes and Natural Killer (NK) cells patterns 
through flow - cytometric analysis of CD3, CD4, CD8, 
CD16 and CD19 expression, to estimate the 
immunoglobulin levels IgG, IgM and IgA in FMF 
patients as compared to normal control subjects, and 
also to scrutinize the possible use of NLR as a marker 
for subclinical inflammation in patients with FMF. 
 
 
Patients and Methods 
 
Forty - two patients with FMF attending the 
Clinical Genetics Clinic at National Research Centre 
were included in this study. They were following up 
patients during the year 2015. They were 13 males 
and 19 females; their age ranged from 2 to 17 years 
old. Twenty normal healthy subjects within the same 
age and sex range were included as a control group. 
All subjects were subjected to full clinical 
examination and history taking. Written consents were 
taken from the children parents’, and the study was 
approved by Medical Ethics Committee of NRC 
(13/146). Complete blood picture was done for all 
cases, and neutrophil/lymphocyte ratio was 
calculated. Flow - cytometer analysis was done for 
CD3, CD4, CD8, CD19 and CD16 using monoclonal 
antibodies [19]. Immunoglobulins IgG, IgA, Ig M was 
estimated in serum using nephelometry [20]. 
Statistical analysis was performed using 
SPSS program version 13. Quantitative variables 
were presented as a mean and standard deviation. 
The unpaired t-test was used to evaluate differences 
between the two groups of continuous variables. Two-
tailed P < 0.05 was considered statistically significant. 
 
 
Results 
 
The study group consisted of 23 males 
(54.8%) and 19 females (45.2%), all were diagnosed 
as FMF and during the attack; while the control group 
were normal subjects matching age and sex. The age 
range in the FMF study group was 2 - 17 years and 2 
- 14 years in the control group respectively (Table 1). 
This study included 42 patients, with the clinical 
characteristics of FMF. Positive consanguinity was 
present in 20 patients (47.6 %). 
Abdominal pain was the most common 
manifestation which usually occurs in repeated 
attacks and stays from 2 hours to several days 
followed by fever, arthritis, and erysipelas-like rashes. 
All the patients were treated with colchicine after 
being identified by molecular diagnosis. 
Table 1: Age and sex of patients and control group 
 Patients n = 42 Control n = 20 
Age range (years) 2-17 2-14 
Sex (male/female) 23/19 11/9 
 
CD3, CD4, and CD8 were statistically 
increased in patients’ group as compared to normal 
control group; p-value were 0.001, 0.002, 0.004, 
respectively (Table 2). While CD16 has statistically 
decreased, the p-value was 0.007 as compared the 
control group. 
Table 2: Cellular expression of CD3, CD4, CD8, CD19 and CD16 
in FMF patients as compared to control group 
 
 
Patients n = 42 Control n = 20 p - value 
CD3 % 51.91 ± 15.19 36.31 ± 10.41 0.001* 
CD19 % 18.29 ± 9.07 19.78 ± 5.38 0.81 
CD16 % 12.81 ± 5.38 19.06 ± 6.9 0.007* 
CD4 % 33.74 ± 6.46 22.88 ± 6.81 0.002* 
CD8 % 19.37 ± 5.98 12.2 ± 4.15 0.004* 
*statistical significant p < 0.05. 
 
Immunoglobulins IgA, IgM, IgG and also TLC 
and N/L ratio did not show the significant statistical 
difference between the patients and control groups 
(Table 3). 
Table 3: Immunoglobulins IgA, IgM, IgG, TLC and N/L ratio in 
FMF patients and control group 
parameters Patients n = 42 Control n = 20 p - value 
TLC (×10
6
 
/mm
3
 
) 7.54 ± 2.39 9.16 ± 2.23 0.13 
N/L ratio (NLR) 1.23 ± 0.62 0.8 ± 0.16 0.10 
IgA (g/L) 1.35 ± 0.7 1.31 ± 1.06 0.89 
IgM (g/L) 1.26 ± 0.45 1.41 ± 0.60 0.54 
IgG (g/L) 10.67 ± 3.8 9.62 ± 3.45 0.49 
*statistical significant p < 0.05 
 
 
 
Discussion 
 
Autoinflammatory diseases originate from 
inappropriate activation of antigen-independent 
inflammatory mechanisms [21]. FMF is characterised 
by fever and serositis which flare up as paroxysmal 
attacks, with intervening asymptomatic periods. The 
attacks of fever and diffuse abdominal pain in FMF 
are characterised by subclinical inflammation and 
associated endothelial dysfunction [11]. We aimed to 
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investigate a possible immune regulation imbalance in 
familial Mediterranean fever (FMF) by measuring 
levels of peripheral blood lymphocyte subsets using 
flow - cytometry. In this study, we found the increased 
percentage of T cells CD3, CD4 and CD8 as 
compared to the control group. This was in agreement 
with Musabak et al., [22], who stated that CD3, CD4 
and CD8 were increased in FMF patients than in the 
control group indicating that the T cell system is 
abnormally activated in patients with FMF. Rimar et 
al., [23] suggested that regulatory T cells play a role in 
cutting short FMF acute attacks. This may explain the 
fact that inflammation in FMF is self - limiting and also 
the absence of autoantibodies, antigen-specific T cells 
and tissue damage [24]. 
NK cells mediate cytotoxicity that is regulated 
by their inhibitory and activating surface receptors. An 
increase in the activation of NK cells may result in 
proliferation and change the immune response [25]. In 
this study, CD16+ NK cells were decreased in FMF 
patients group as compared to the control group in 
contrary to what was reported that NK cell numbers 
were significantly increased in FMF patients as 
compared to controls. In autoinflammatory diseases, 
dysregulation is believed to occur in the innate 
immune system without primary involvement of T and 
B lymphocytes. Nevertheless, autoinflammation 
involves crosstalk between the innate immune system 
– neutrophils, macrophages, and NK cells – with the 
adaptive immune system [26]. 
To investigate the B - cells, CD19 showed no 
significant difference between patients and control 
groups. As regards to serum immunoglobulins IgA, 
IgM and IgG estimated in this study, there was no 
statistically significant difference in patients when 
compared to the control group. In another genetic 
disease, results obtained showed a significant 
difference between patients and controls, in which the 
results of the control group is nearly the same [27]. 
However, Livneh et al., [28] compared the 
immunoglobulin levels in patients with FMF about 
patients with hyperimmunoglobulinemia D syndrome 
(HIDS) and not about healthy control subjects, and 
that the patients with HIDS showed the significantly 
higher prevalence of elevated immunoglobulins levels 
than patients with FMF. 
The N/L ratio is a reliable marker for 
evaluating and monitoring the systemic inflammatory 
response, and prognosis of clinical outcome of 
inflammatory diseases [29]. 
No statistically significant difference was 
detected in TLC nor NLR in FMF patients as 
compared to the control group while Özer et al., [30] 
and Duksal et al., [29], found TLC and N/L ratio were 
significantly higher in children with FMF than in 
healthy individuals. Celikbilek et al., [31], reported that 
the N/L ratio was higher in active FMF than in FMF in 
remission as well as in control subjects. 
In conclusion, dysfunction of the innate 
immune system is the central matter in FMF as a self - 
reactive autoinﬂammatory disease. 
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